Welcome to our dedicated page for Nutriband news (Ticker: NTRBW), a resource for investors and traders seeking the latest updates and insights on Nutriband stock.
Company Overview
Nutriband Inc. is a specialized pharmaceutical company based in Oviedo, Florida, that focuses on cutting-edge transdermal and topical technologies. The company has built its expertise around developing a portfolio of innovative transdermal products, with a primary focus on its abuse-deterrent technology known as AVERSA. This proprietary technology integrates aversive agents into transdermal patches to prevent abuse, misuse, diversion, and accidental exposure of drugs with high abuse potential, such as opioids and stimulants.
Core Business and Product Portfolio
The centerpiece of Nutriband’s portfolio is its lead product under development, an abuse-deterrent fentanyl patch that incorporates AVERSA technology. By employing a unique coating mechanism that leverages taste aversion, the patch is designed to deter the oral abuse of potent medications while ensuring that patients in need retain access to essential pain management solutions. The company also extends its technological expertise to other product categories, including transdermal consumer goods and a mosquito repellent patch, evidencing a diverse application of its platform.
Innovative Technology and Intellectual Property
Nutriband’s AVERSA technology is at the forefront of addressing the challenges posed by the global opioid crisis. The unique methodology of incorporating aversive agents, such as the well-known bitter compound Bitrex®, into patches is underpinned by a robust international intellectual property portfolio, with patents granted in 46 countries. This extensive protection not only reinforces the company’s market position but also demonstrates its commitment to innovation and drug safety.
Strategic Partnerships and Operational Excellence
The company has established strategic alliances with prominent partners in the pharmaceutical and manufacturing sectors. Its collaboration with Kindeva Drug Delivery enables Nutriband to integrate its abuse-deterrent technology into FDA-approved transdermal systems, thereby optimizing the manufacturing and regulatory pathway for its lead products. Additionally, Nutriband’s subsidiary, Pocono Pharma, bolsters its contract manufacturing services, distributing a variety of products to major retail channels across the United States.
Market Position and Business Model
Nutriband positions itself within a highly specialized niche of the pharmaceutical industry, focusing on transdermal applications that enhance drug safety while combating abuse potential. The company generates revenue primarily through the sale of its consumer transdermal products and contract manufacturing services, coupled with the anticipated benefits from its innovative abuse-deterrent technology. By streamlining regulatory processes and leveraging a single Phase 1 trial for its abuse-deterrent product, Nutriband demonstrates a pragmatic approach to market entry while ensuring rigorous compliance with safety standards.
Commitment to Safety and Market Impact
At its core, Nutriband is dedicated to addressing critical public health challenges by improving the safety profile of transdermal pharmaceutical products. The incorporation of AVERSA technology into products such as a fentanyl patch not only aims to reduce the risk of misuse and diversion but also helps prevent accidental exposure, which is particularly important in vulnerable populations. This dual focus on efficacy and safety underscores the company’s role in mitigating the impact of drug abuse while supporting the legitimate medical needs of patients.
Conclusion
Overall, Nutriband Inc. represents a blend of technological innovation, strategic operational partnerships, and a deep commitment to enhancing drug safety. Its comprehensive approach in leveraging abuse-deterrent transdermal technology sets it apart in a competitive industry. Investors and analysts looking for insights into innovative pharmaceutical strategies will find Nutriband’s focus on sustainable, safety-driven solutions to be of considerable significance.
Nutriband Inc. (NASDAQ:NTRB) has announced signing an Associate Partnership agreement with Charlotte FC. The partnership aims to increase visibility for Nutriband's products, particularly AI Tape, which is manufactured at their Pocono Pharmaceutical facility in North Carolina.
The company plans to leverage this partnership to promote their AVERSA platform technology, which they position as potentially becoming the world's first abuse deterrent patch platform for chronic pain management.
Nutriband Inc. (NASDAQ:NTRB) has announced a new Associate Partnership agreement with Charlotte FC. The partnership aims to increase visibility for Nutriband's products, particularly AI Tape, which is manufactured at their Pocono Pharmaceutical facility in North Carolina.
The company plans to leverage this partnership to promote their AVERSA platform technology, which is being developed as a potential first-of-its-kind abuse deterrent patch platform for chronic pain management.
Nutriband (NASDAQ: NTRB) has secured a Certificate of Registration from the USPTO for trademark registration Number 7,692,920 on February 18, 2025. The trademark covers product research and development, scientific research and development, biochemical research and development, and pharmaceutical research and development under Class 042.
The Nutriband™ trademark is important for commercializing the company's AVERSA platform technology, designed to prevent abuse, diversion, misuse, and accidental exposure of drugs with abuse potential in transdermal patches. The company's leading product, AVERSA™ Fentanyl, is being developed in partnership with Kindeva Drug Delivery, focusing on scaling up commercial manufacturing before FDA submission. Market analysis by Health Advances projects potential peak annual U.S. sales of $80-200 million for AVERSA™ Fentanyl.
Nutriband Inc. (NASDAQ:NTRB) has formalized an exclusive development partnership with Kindeva Drug Delivery for Aversa™ Fentanyl, an abuse-deterrent fentanyl patch. The partnership involves shared development costs in exchange for milestone payments. The product combines Nutriband's Aversa™ abuse-deterrent technology with Kindeva's FDA-approved fentanyl patch.
The Aversa™ technology incorporates aversive agents into transdermal patches to prevent abuse, diversion, misuse, and accidental exposure of drugs with abuse potential. The technology is protected by patents in 46 countries, including major markets like the US, Europe, Japan, and China. If successful, Aversa Fentanyl would become the world's first abuse-deterrent opioid patch, with potential peak annual US sales ranging from $80 million to $200 million.
Nutriband Inc. (NASDAQ: NTRB) has announced the appointment of World and European Wrestling Gold medalist and Olympic Silver medalist Anastasia Nichita to its Product Advisory Board. The appointment aims to expand the Nutriband Brand and promote its over-the-counter sports and consumer products internationally.
The company, which develops transdermal pharmaceutical products through its subsidiary Pocono Pharma, produces multiple products including AI Tape. This product combines traditional kinesiology tape benefits with soothing and therapeutic ingredients in a proprietary adhesive mix.
Nutriband Inc. (NASDAQ:NTRB) has received a Notice of Allowance from the USPTO for patent application 18/369,241, covering its Aversa™ abuse deterrent technology. This technology is designed to prevent abuse, diversion, misuse, and accidental exposure of drugs with abuse potential in transdermal patches.
The company's lead product, Aversa™ Fentanyl, aims to become the first abuse-deterrent fentanyl transdermal system. The technology utilizes a proprietary aversive agent coating that employs taste aversion to deter oral abuse. The intellectual property is protected by patents in 46 countries, including major markets like the US, Europe, Japan, and China.
According to a market analysis report, Aversa Fentanyl has the potential to achieve peak annual US sales between $80 million to $200 million.
Nutriband (NASDAQ: NTRB) has released its 2024 shareholder letter highlighting significant achievements and 2025 outlook. The company reported record Q3 revenue of $645,796, a 51% year-over-year increase. Key developments include advancing their AVERSA™ Fentanyl product, projected to achieve peak annual U.S. sales of $80-200 million, toward commercialization with partner Kindeva Drug Delivery.
The company secured patent approvals in China and Hong Kong, expanding their intellectual property portfolio to 46 countries. Nutriband raised $8.4 million through a private placement and established an exclusive supplier agreement with Fit For Life Group for major fitness brands. The company plans to submit the New Drug Application (NDA) for AVERSA™ Fentanyl in 2025, with potential regulatory approval expected by year-end.
Nutriband Inc. (NASDAQ:NTRB) has extended its Chinese patent to Macao for its AVERSA™ abuse-deterrent transdermal technology, bringing the total patent coverage to 46 countries and territories. The Macao IP Office assigned patent number J/9010, effective December 17, 2024.
The AVERSA™ technology incorporates aversive agents into transdermal patches to prevent abuse, diversion, misuse, and accidental exposure of drugs with abuse potential. Nutriband is collaborating with Kindeva Drug Delivery to develop AVERSA™ Fentanyl, targeting FDA approval in the first half of 2025. The product has potential peak annual US sales of $80-200 million and aims to be the world's first abuse-deterrent opioid patch.
Nutriband Inc. (NASDAQ:NTRB) reported strong Q3 2024 financial results, with record revenue of $645,796, up 50.94% year-over-year. The company maintains a solid cash position of $5.7 million, with total assets of $12.55 million and stockholders' equity of $11.23 million.
Through its Pocono Pharma subsidiary, Nutriband is expanding its kinesiology tape manufacturing services, with products available in major retailers like Target, Walmart, Walgreens, and CVS. The company continues to progress with AVERSA Fentanyl development, targeting NDA submission in first half of 2025, requiring only a single phase 1 Human Abuse Potential study.
Market analysis projects potential peak annual sales of $80-$200 million for AVERSA Fentanyl and up to $130 million for AVERSA Buprenorphine.
Nutriband Inc. (Nasdaq: NTRB) has announced its participation in the Noble Conference at Florida Atlantic University in Boca Raton on December 3rd-4th, 2024. Company President and Chairman Serguei Melnik will present on December 4th at 1:30 PM in Conference Room 3, focusing on the company's AVERSA technology.
The company specializes in developing transdermal pharmaceutical products, with their flagship product being an abuse-deterrent fentanyl patch incorporating AVERSA™ technology. This innovative technology can be integrated into any transdermal patch to prevent abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.
Presentation details and replay will be available on Channelchek and Youtube after the conference.